Sio Gene Therapies Stock Börse Stuttgart

6YY

US8293991043

Delayed Börse Stuttgart Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-1.65%	-16.01%

27/03/23	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	CI
22/03/23	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	CI

Latest news : Sio Gene Therapies

27/03/23	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	CI
22/03/23	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	CI
14/02/23	Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	CI
15/12/22	Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	MT
10/11/22	Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	CI
11/08/22	Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	CI
20/06/22	Sio Gene Therapies Inc.(NasdaqGS:SIOX) dropped from S&P Global BMI Index	CI
14/06/22	Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	CI
14/06/22	Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	CI
28/04/22	HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	MT
28/04/22	Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	MT
28/04/22	Top Premarket Decliners	MT
27/04/22	Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	CI

More news

Analysts' recommendations: Sio Gene Therapies

28/04/22	HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	MT
28/04/22	Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	MT
01/02/22	Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating	MT
01/02/22	HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating	MT
01/02/22	SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6	MT

More recommendations

Press Releases: Sio Gene Therapies

02/02/24	Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	AQ
02/02/24	Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	GL
07/04/23	SIO GENE THERAPIES INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
16/03/23	Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	PU
16/03/23	SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ

More press releases

Managers and Directors: Sio Gene Therapies

Manager	Title	Age	Since
David Nassif CEO	Chief Executive Officer	72	31/01/2022

Director	Title	Age	Since
David Nassif BRD	Director/Board Member	72	31/01/2022

More insiders

Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.

Employees

Sector

More about the company